PIRS - Pieris Pharmaceuticals Inc
IEX Last Trade
18.055
-0.415 -2.299%
Share volume: 9,135
Last Updated: Fri 30 Aug 2024 08:44:37 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$18.47
-0.42
-2.25%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-04 | 2023-03-31 | 2023-05-11 | 2023-08-10 | 2023-11-14 | 2024-03-29 | 2024-05-15 | |
| Total revenue | 3.698 M | 5.370 M | 5.846 M | 1.936 M | 20.055 M | 19.520 M | 1.299 M | 53.000 K | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 3.698 M | 5.370 M | 5.846 M | 1.936 M | 20.055 M | 19.520 M | 1.299 M | 53.000 K | |
| 45.21% | 8.86% | -66.88% | 935.90% | -2.67% | -93.35% | -95.92% | |||
| Operating expenses | 16.028 M | 17.538 M | 17.365 M | 17.447 M | 17.992 M | 16.434 M | 6.781 M | 5.356 M | |
| Selling general and admin | 4.081 M | 3.949 M | 3.985 M | 4.023 M | 3.664 M | 6.839 M | 2.327 M | 4.138 M | |
| Research and development | 11.947 M | 13.589 M | 13.380 M | 13.424 M | 14.328 M | 9.595 M | 4.454 M | 1.218 M | |
| Total expenses | 16.028 M | 17.538 M | 17.365 M | 17.447 M | 17.992 M | 16.434 M | 6.781 M | 5.356 M | |
| 9.42% | -0.99% | 0.47% | 3.12% | -8.66% | -58.74% | -21.01% | |||
| Operating income | -12.330 M | -12.168 M | -11.519 M | -15.511 M | 2.063 M | 3.086 M | -5.482 M | -5.303 M | |
| Ebit | -12.330 M | -12.168 M | -11.519 M | -15.511 M | 2.063 M | 3.086 M | -5.482 M | -5.303 M | |
| Pretax income | -10.338 M | -9.736 M | -8.102 M | -13.183 M | 3.976 M | -10.752 M | -4.584 M | -4.892 M | |
| -5.82% | -16.78% | 62.71% | -130.16% | -370.42% | -57.37% | 6.72% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -10.338 M | -9.736 M | -8.102 M | -13.183 M | 3.976 M | -10.752 M | -4.584 M | -4.892 M | |
| 5.82% | 16.78% | -62.71% | 130.16% | -370.42% | 57.37% | -6.72% | |||
| Net income | -10.338 M | -9.736 M | -8.102 M | -13.183 M | 3.976 M | -10.752 M | -4.584 M | -4.892 M | |
| 5.82% | 16.78% | -62.71% | 130.16% | -370.42% | 57.37% | -6.72% |